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Erythropoietin prevents sepsis-related acute kidney injury in rats by
inhibiting nuclear factor-B and upregulating endothelial nitric oxide
synthase. Am J Physiol Renal Physiol 302: F1045–F1054, 2012. First
published January 11, 2012; doi:10.1152/ajprenal.00148.2011.—The
pathophysiology of sepsis involves complex cytokine and inflamma-
tory mediator networks, a mechanism to which NF-B activation is
central. Downregulation of endothelial nitric oxide synthase (eNOS)
contributes to sepsis-induced endothelial dysfunction. Erythropoietin
(EPO) has emerged as a major tissue-protective cytokine in the setting
of stress. We investigated the role of EPO in sepsis-related acute
kidney injury using a cecal ligation and puncture (CLP) model. Wistar
rats were divided into three primary groups: control (sham-operated);
CLP; and CLPEPO. EPO (4,000 IU/kg body wt ip) was adminis-
tered 24 and 1 h before CLP. Another group of rats received N-nitro-
L-arginine methyl ester (L-NAME) simultaneously with EPO admin-
istration (CLPEPOL-NAME). A fifth group (CLPEPOtreat)
received EPO at 1 and 4 h after CLP. At 48 h postprocedure,
CLPEPO rats presented significantly higher inulin clearance than
did CLP and CLPEPOL-NAME rats; hematocrit levels, mean
arterial pressure, and metabolic balance remained unchanged in
the CLPEPO rats; and inulin clearance was significantly higher
in CLPEPOtreat rats than in CLP rats. At 48 h after CLP,
creatinine clearance was significantly higher in the CLPEPO rats
than in the CLP rats. In renal tissue, pre-CLP EPO administration
prevented the sepsis-induced increase in macrophage infiltration,
as well as preserving eNOS expression, EPO receptor (EpoR)
expression, IKK- activation, NF-B activation, and inflammatory
cytokine levels, thereby increasing survival. We conclude that this
protection, which appears to be dependent on EpoR activation and
on eNOS expression, is attributable, in part, to inhibition of the
inflammatory response via NF-B downregulation.
THE MORTALITY RATES OF SEPSIS and septic shock remain unac-
ceptably high and have not changed in several decades (5, 6,
26, 30). Acute kidney injury (AKI) occurs in50% of patients
with sepsis (5, 30). In such patients, the development of AKI is
predictive of a poor outcome, and the consequent mortality has
been reported to be as high as 70% (5). Despite improved
strategies for supporting vital organs and resuscitating patients,
the incidence and mortality rates of septic AKI remain quite
high (5, 6). The prevention of kidney injury in intensive care
settings continues to represent a great challenge.
It has been shown that NF-B mediates the transcription of
a large number of genes, the products of which are known to
play important roles in septic pathophysiology (24, 31). Mice
deficient in those NF-B-dependent genes are resistant to the
development of septic shock and to sepsis-related mortality
(31). More importantly, blockade of the NF-B pathway cor-
rects septic abnormalities. In sepsis, inhibition of NF-B acti-
vation restores systemic hypotension, ameliorates myocardial
dysfunction, corrects vascular derangement, inhibits multiple
proinflammatory gene expression, diminishes intravascular co-
agulation, reduces tissue neutrophil influx, and prevents mi-
crovascular endothelial leakage (31). Therefore, NF-B acti-
vation plays a central role in the pathophysiology of septic
shock (31, 36).
Studies have indicated that downregulation of vascular en-
dothelial nitric oxide synthase (eNOS) contributes to vascular
hyporesponsiveness in sepsis (51). In animals submitted to
cecal ligation and puncture (CLP), it has been shown that there
is a significantly reduction in the extent of the eNOS-immu-
noreactive positive area in endothelial cells (51). In the CLP
model, the decreased eNOS in vascular endothelial cells is at
least partially responsible for endothelial cell dysfunction (52).
In addition, Ckless et al. (9) suggest that arginase regulates
NF-B via nitric oxide (NO)-dependent redox changes. These
findings have implications for the pathophysiology of chronic
inflammatory conditions (9).
Erythropoietin (EPO) is a growth hormone, and its principal
physiological function is the induction of erythropoiesis. For
the last two decades, EPO has been used in the management of
anemia associated with end-stage renal disease (18). Recent
studies have shown that, in addition to its hematopoietic
activity, EPO has a cytoprotective effect on many different
types of cells and tissues (4, 41). There are EPO receptors
(EpoRs) widely distributed throughout a number of tissue types
(48). The discovery that EpoRs are expressed in glomerular,
mesangial, and tubular epithelial cells in human, rat, and
mouse kidneys have prompted studies of the effects of EPO in
small-rodent models of AKI (41, 44). Such studies have shown
that EPO not only stimulates erythropoiesis but also has anti-
inflammatory properties, as well as exerting the following
effects (7, 19, 21, 38): reducing apoptosis, oxidative stress, and
lipid peroxidation; promoting renal tubular cell regeneration,
vascular regeneration, and neoangiogenesis; mobilizing endo-
thelial progenitor cells; and upregulating eNOS expression. It
is also known that EPO mediates neuroprotection against
axonopathy and apoptosis in the peripheral nervous system by
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inhibiting NF-B activation, indicating rescue from an injury
phenotype (44).
In a model of LPS-induced endotoxemia, EPO was found to
significantly attenuate renal dysfunction. This EPO-related
renal protection was associated with reversal of the effects that
the endotoxin has on renal superoxide dismutase (35).
Various preclinical animal models have been developed to
evaluate the effect of sepsis on the development of AKI. The
CLP model is widely used because the resulting polymicrobial
sepsis mimics many features of human sepsis (8, 13, 46, 49).
In the present study, we attempted to determine whether
EPO prevents the renal dysfunction seen in the CLP model of
sepsis. We also tested whether EPO could be used as thera-
peutic agent after the induction of the CLP sepsis. We tested
the hypothesis that the mechanism of renal dysfunction in the
CLP model of sepsis is mediated, at least in part, by NF-B
upregulation and eNOS downregulation. We further hypothe-
sized that EPO protects renal function by regulating the protein
expression of NF-B, eNOS, and EpoR.
METHODS
Animals and experimental protocols. Male Wistar rats, 8 wk old
and weighing 180–230 g, were obtained from the animal facility of
the University of São Paulo School of Medicine. Animals were fed
standard rat chow and given ad libitum access to tap water. Before the
experiments outlined below, the rats were randomly divided into three
groups: control, consisting of untreated, sham-operated rats; CLP,
consisting of untreated rats submitted to CLP; and CLPEPO, con-
sisting of rats intraperitoneally injected with 4,000 IU/kg body wt
(BW) of EPO (Hemax; Biosintética, Uberabinha, Brazil) at 24 and 1
h before CLP.
To analyze the early effects of EPO administration on renal
function, we conducted one set of experiments at 24 h after CLP or
sham surgery (control, n  5; CLP, n  7; and CLPEPO, n  7).
In this first set of experiments, we measured inulin clearance, mean
arterial pressure (MAP), hematocrit, and microvascular perfusion.
In a second set of experiments, the late effects of EPO were
analyzed at 48 h after CLP or sham surgery (control, n  10; CLP,
n  10; and CLPEPO, n  10). In this second set of experiments,
we quantified renal function by measuring creatinine clearance. This
set of experiments also included 12-h metabolic cage studies, as well
as immunohistochemical analysis to study the expression of NF-B.
We also performed immunoblotting studies to determine the expres-
sion of eNOS and of the IB kinase -subunit (IKK-). We conducted
a third set of experiments to plot the survival curves for the animals
submitted to CLP (CLP, n  9; and CLPEPO, n  9).
In a fourth set of experiments, we investigated the therapeutic
effect that post-CLP EPO administration has on AKI. In this fourth set
of experiments, rats received EPO (4,000 IU/kg BW ip) at 1 and 4 h
after CLP (CLPEPOtreat, n 4), and we measured inulin clearance
at 24 h after the CLP surgery.
An additional group of rats (n 5), not submitted to CLP, received
a single dose of EPO (4,000 IU/kg BW ip) and were evaluated 5 wk
later to identify adverse effects such as polycythemia and thrombosis,
as well as other complications. We compared those animals with a
control group (n  5) in terms of hematocrit levels. In another group
of rats not submitted to CLP but receiving EPO (4,000 IU/kg BW ip;
n  7), we measured MAP at 24 h after EPO administration.
To determine whether the beneficial effects of EPO treatment are
mediated by NO production, rats were submitted to inhibition of NOS
activity, receiving N-nitro-L-arginine methyl ester (L-NAME) simul-
taneously with EPO administration. At 24 h before CLP, and again at
1 h before CLP, we administered L-NAME (10 mg/kg BW iv; Sigma,
St. Louis, MO) and EPO (4,000 IU/kg BW ip). In this group of rats,
designated the CLPEPOL-NAME group (n  10), we measured
inulin clearance and MAP at 24 h after CLP. The experimental
protocols were approved by the Research Ethics Committee of the
University of São Paulo School of Medicine Hospital das Clínicas.
CLP procedures. Rats were anesthetized with 2.5% 2,2,2-tribro-
moethanol (99%), after which a midline incision was made and the
cecum exposed. A 4-0 silk ligature was placed 1.5 cm from the cecal
tip. The cecum was punctured twice with an 14-G needle and gently
squeezed to confirm leakage of cecal contents. The abdominal incision
was closed in two layers with 3-0 silk sutures. Control group animals
were submitted to the same procedure, minus the ligation and punc-
ture. To ensure adequate fluid resuscitation, each animal received an
injection of 0.15 M NaCl (25 ml/kg ip) immediately after the proce-
dure. Additional fluid therapy (0.15 M NaCl, 25 ml/kg ip) was started
at 6 h after CLP and then repeated every 12 h, as was antibiotic
therapy with imipenem/cilastatin (14 mg/kg ip; Merck Sharp &
Dohme, West Point, PA).
Inulin clearance studies. At 24 h after CLP or sham surgery, each
designated animal was anesthetized with thiopental sodium (50 mg/kg
BW ip). The trachea was then cannulated with a polyethylene (PE)-
240 catheter, and spontaneous breathing was maintained. To control
MAP and allow blood sampling, a PE-60 catheter was inserted into
the right carotid artery. To collect urine samples, a suprapubic incision
was made and the urinary bladder was cannulated with a PE-240
catheter. A loading dose of inulin (100 ml/kg BW, diluted in 0.9%
saline) was then administered through the jugular vein. Constant
infusion of inulin (10 mg/kg BW) was then started and continued at
0.04 ml/min throughout the experiment. A total of three urine samples
were collected at 30-min intervals. Blood samples were obtained at
the beginning and the end of the experiment.
Light microscopy and immunohistochemistry. The kidneys were
flushed with PBS (0.15 M NaCl and 0.01 M phosphate buffer, pH 7.4)
injected into the aortic artery. A fragment of the right kidney was
immersed in methacarn (60% methanol, 30% chloroform, and 10%
acetic acid), where it remained for 24 h, after which the methacarn
was replaced with 70% ethanol. Another fragment of the right kidney
was frozen in liquid nitrogen and stored at 80°C for Western
blotting. After removal of the right kidney, the left kidney was flushed
with a 4% paraformaldehyde solution injected into the aortic artery.
The left kidney was then removed. A fragment of the left kidney was
immersed in 4% paraformaldehyde, where it remained for 2 h, after
which it was postfixed in Bouin’s solution for 4 h. Bouin’s solution
was then removed, and the tissue fragment was dehydrated in 70%
ethanol. The fragments (from the right and left kidney) were then
embedded in paraffin and cut into 4-m sections. The sections were
deparaffinized, after which they were subjected to Masson’s trichrome
staining for determination of the fractional interstitial area or were
used in the immunohistochemical studies.
The fractional interstitial area of the renal cortex was determined
by morphometry with a video camera connected to an image analyzer
(QWin; Leica, Wetzlar, Germany). In each renal cortex, 20 grid fields
(each measuring 37,000 m2) were evaluated. Interstitial areas were
first manually encircled on a video screen and then quantified by
computerized morphometry (47).
For ED1 and NF-B immunostaining, samples were processed in
4-m paraffin sections. After deparaffinization, endogenous peroxi-
dase activity was blocked with 0.3% H2O2 in water for 10 min at room
temperature. Sections were then subjected to incubation overnight at
4°C with an anti-ED1 antibody (1:1,000) or anti-NF-B antibody
(1:80). This was followed by incubation with biotinylated mouse
anti-rat IgG for 30 min at room temperature. The reaction product was
detected with an avidin-biotin-peroxidase complex (Vector Laborato-
ries, Burlingame, CA). The color reaction was developed with 3,3-
diaminobenzidine (Sigma), and the sections were counterstained with
methyl green.
For all sections, negative controls consisted of replacing the pri-
mary antibody with equivalent concentrations of an irrelevant normal
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rabbit or normal goat IgG. The sections were examined under light
microscopy at a magnification of 400.
For evaluation of immunoperoxidase staining for NF-B, each
tubulointerstitial grid field was graded semiquantitatively, and the
mean score per kidney was calculated. Each score reflected mainly
changes in the extent, rather than the intensity, of staining, based on
the proportion of the grid field showing positive staining: 0, absent or
	5%; I, 5–25%; II, 25–50%; III, 50–75%, and IV, 
75%.
To obtain the mean numbers of infiltrating macrophage/monocyte-
positive cells in the renal cortical tubulointerstitium, 30 grid fields
measuring 0.245 mm2 each were evaluated and the mean counts per
kidney were calculated.
Light microscopy studies. The kidneys were removed, sectioned
transversely, fixed in 4% paraformaldehyde, postfixed in Bouin’s
solution for 4–6 h, and processed for paraffin embedding. Histolog-
ical sections (4-m thick) were stained with Masson’s trichrome and
examined under light microscopy. Tubulointerstitial damage was
defined as tubular necrosis, inflammatory cell infiltrate, tubular lumen
dilation, or tubular atrophy. Damage was graded on a scale of 0 to 4
based on the proportion of the cortex and outer medulla involved (0
no involvement; 0.5  small focal areas; 1  	10%; 2  10–25%;
3  25–75%; 4  
75%), as previously described (42).
Analysis of blood and urine samples. In blood samples obtained 48
h after CLP, plasma levels of creatinine were measured using an
automated colormetric assay. The volume of each 12-h urine sample
was measured gravimetrically. Urine samples were centrifuged in
aliquots to remove suspended material, and the supernatants were
analyzed. Urinary levels of creatinine were also measured using the
same techniques. In blood samples obtained at the end of the creati-
nine clearance study, hematocrit was determined using a microhema-
tocrit capillary tube (Perfecta, São Paulo, Brazil). Serum lactate and
bicarbonate were measured with a blood-gas analyzer (Radiometer
Medical, Copenhagen, Denmark).
Antibodies. Peptide-derived polyclonal anti-eNOS antibody was
obtained from Transduction Laboratories (Lexington, KY). Peptide-
derived polyclonal anti-NF-B and anti-IKK- antibodies were ob-
tained from Santa Cruz Biotechnology (Santa Cruz, CA). Peptide-
derived polyclonal anti-ED1 antibody was obtained from Serotec
(Oxford, UK). Peptide-derived polyclonal anti-EpoR antibody was
also obtained from Santa Cruz Biotechnology.
Preparation of membrane fractions. Samples of kidneys were
homogenized with a Teflon pestle glass homogenizer (Schmidt and
Co., Frankfurt am Main, Germany) in ice-cold isolation solution (200
mM mannitol, 80 mM HEPES, and 41 mM KOH, pH 7.5) containing
protease inhibitors (protease inhibitor cocktail; Sigma). The homog-
enates were centrifuged at low speed (2,000 g) for 15 min at 4°C to
remove nuclei and cell debris.
Preparation of cytoplasmic protein extracts. Kidney samples were
cut into small pieces, washed with PBS, and centrifuged. The pellet
was homogenized using a tissue grinder, and the cytoplasmic protein
was extracted with a commercial kit (Ne-Per Nuclear and Cytoplas-
mic Protein Extraction Kit; Pierce Biotechnology, Rockford, IL), in
accordance with the manufacturer’s instructions.
Electrophoresis and immunoblotting. Samples of membrane frac-
tions or kidney samples were run on 10% polyacrylamide minigels
(for eNOS, EpoR, and IKK-). After transfer by electroelution to
nitrocellulose membranes (PolyScreen, PVDF Transfer; Life Science
Products, Boston, MA), blots were blocked with 5% milk and 0.1%
Tween 20 in TBS for 1 h. Blots were then incubated overnight with
the antibodies anti-eNOS (1:2,000), anti-EpoR (1:500), and anti-
IKK- (1:1,000). The labeling was visualized with horseradish per-
oxidase-conjugated secondary antibody using the enhanced chemilu-
minescence (ECL) detection system (Amersham Pharmacia Biotech,
Piscataway, NJ).
Quantification of renal expression of eNOS, EpoR, and IKK-. The
ECL films were scanned using Image Master VDS software (Phar-
macia Biotech, Uppsala, Sweden). Quantitative analysis of antibodies
was performed using densitometry. The bands were normalized to
actin protein expression.
Survival study. Following another set of the experiments described
above (CLP and EPO administration), survival curves were plotted,
initially at 6 h after CLP and then every 6–12 h, for a total of 60 h.
Measurement of renal tissue levels of inflammatory cytokines.
Renal tissue levels of cytokine were measured and analyzed with the
Bio-Plex system. A Bio-Plex rat 9-Plex cytokine assay kit (Bio-Rad
Laboratories, Hercules, CA) was used to test samples for the presence
of IL-1a, IL-1b, IL-2, IL-4, IL-6, IL-10, colony-stimulating factor,
IFN-, and TNF-. The assay was read on the Bio-Plex suspension
array system, and the data were analyzed using Bio-Plex Manager
software, version 4.0. Standard curves ranged from 32,000 to 1.95
pg/ml. Data are expressed as cytokine level (pg/ml) per protein level
of renal tissue extract (g/ml).
Statistical analysis. All quantitative data are expressed as means 
SE. Differences among the means of multiple parameters were ana-
lyzed by ANOVA followed by the Student-Newman-Keuls test.
Differences between two parameters were analyzed either by unpaired
t-test or by nonparametric methods (Mann-Whitney test). Survival
analyses were compared by a log-rank test. Values of P 	 0.05 were
considered statistically significant.
RESULTS
Early post-CLP EPO effects on inulin clearance. As can be
seen in Table 1, inulin clearance at 24 h after CLP or sham
surgery was lower in the CLP rats than in the control rats (CLP:
0.43 0.08 vs. 0.83 0.04 ml·min1·100 g BW1, P	 0.01),
as would be expected. At the same time point, inulin clearance
was also significantly lower in the CLP rats than in the
CLPEPO rats (0.43  0.08 vs. 0.99  0.12 ml·min1·100 g
BW1, P 	 0.001), although there was no significant differ-
ence between the CLPEPO rats and the control rats (Fig. 1A).
Early post-CLP EPO effects on hematocrit values. At 24 h
postprocedure, hematocrit values were markedly lower in CLP
rats than in control rats, whereas there was no such decrease in
hematocrit levels in the CLPEPO rats (Table 1).
Early post-CLP EPO effects on hemodynamic and metabolic
acid-base status. At 24 h after CLP or sham surgery, MAP
(mmHg) was completely preserved (at normal levels) in
CLPEPO rats (Table 1). We also found no significant differ-
ence between the rats not submitted to CLP or sham surgery
but receiving EPO and the control (sham-operated only) rats in
terms of the MAP at 24 h after EPO administration (107  6.6
Table 1. Effects of erythropoietin on hemodynamic and






ml  min1  100 g BW1 0.82  0.04 0.43  0.08a,b 0.99  0.12
Mean arterial pressure,
mmHg 112 2.5 74  7.5c,d 99  2.3
Hematocrit, % 43.0 1.0 34.4  2.5e,f 41.4  2.0e
Bicarbonate, meq/l 26 1.3 21  1.4e,d 27  1.0
Base excess 1.5 0.5 2.3  1.8e,d 3.2  0.7
Lactate, mmol/l 1.4 0.6 4.3  2.0a,d 2.1  1.1
Values are means  SE. CLP, cecal ligation and puncture; EPO, erythro-
poietin; BW, body weight. aP 	 0.01 vs. control. bP 	 0.001 vs. CLPEPO.
cP 	 0.001 vs. control. dP 	 0.01 vs. CLPEPO. eP 	 0.05 vs. control. fP 	
0.05 vs. CLPEPO.
F1047EPO REVERSES SEPSIS-RELATED AKI
AJP-Renal Physiol • doi:10.1152/ajprenal.00148.2011 • www.ajprenal.org
vs. 112  2.5 mmHg). In addition, EPO administration pre-
vented the systemic hemodynamic abnormalities seen in the
CLP rats (Table 1). Furthermore, EPO administration com-
pletely sustained serum levels of lactate and bicarbonate, as
well as the base excess. It is known that sepsis increases serum
levels of lactate and can cause metabolic acidosis. Serum levels
of lactate were significantly lower in CLPEPO rats than in
CLP rats (Table 1).
Late post-CLP EPO effects on creatinine clearance and
MAP. At 48 h after CLP or sham surgery, creatinine clearance
was significantly higher in CLPEPO rats than in CLP rats
(0.98  0.08 vs. 0.56  0.1 ml·min1·100 g BW1, P 	
0.001). As shown in Fig. 1B, there was no significant differ-
ence between the CLPEPO rats and the control rats (0.98 
0.08 vs. 1.14  0.1 ml·min1·100 g BW1). EPO administra-
tion completely prevented the drop in MAP seen in the un-
treated animals at 48 h after CLP (CLP: 76  7.5 mmHg;
CLPEPO: 97.5  3.1 mmHg, P 	 0.05). As expected, MAP
was significantly lower in the CLP group than in the control
group (76  7.5 vs. 109  3.0 mmHg, P 	 0.01), although
there was no statistical difference between the CLPEPO and
control groups.
Late post-CLP EPO effects on fractional interstitial area. As
can be seen in Fig. 2, A–C, there were marked histological
differences between the CLP group and the CLPEPO group
at 48 h after CLP. In the CLP group, the fractional interstitial
area was significantly greater than that observed in the control
group (Fig. 2D). However, at 48 h post-CLP, the fractional
interstitial area was markedly lower in the CLPEPO group
than in the CLP group. Nevertheless, there was no significant
difference between the CLPEPO and control groups in terms
of the fractional interstitial area.
Late post-CLP EPO effects on renal macrophage infiltration. As
can be seen in Fig. 3, A–C, the number of cells presenting ED1
staining for macrophages/monocytes in the tubulointerstitium
at 48 h after the surgical procedures was significantly higher in
Fig. 1. Renal function measured by inulin
clearance at 24 h after CLP surgery (A) and
creatinine clearance at 48 h after cecal liga-
tion and puncture (CLP; B) or sham surgery
in control rats, rats subjected to CLP only,
and rats subjected to CLP/receiving erythro-
poietin (CLPEPO rats).
Fig. 2. Representative photomicrographs of the fractional interstitial area at 48 h after CLP or sham surgery. A: control group rat. B: CLP group rat. C: CLPEPO
group rat. D: graph (fractional interstitial area). Values are means  SE.
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the CLP group rats than in the control group rats (23.2  3.7
vs. 7.3  0.74 cells/0.245 mm2, P 	 0.001). However, the
numbers of infiltrating macrophages/monocytes were signifi-
cantly lower in the CLPEPO rats than in the CLP rats (7.5 
0.8 vs. 23.2  3.7 cells/0.245 mm2, P 	 0.001).
Late post-CLP EPO effects on NF-B activation. At 48 h
postprocedure, staining for NF-B in the tubulointerstitium of
the renal cortex was more pronounced in CLP rats than in
control rats (1.32  0.08 vs. 0.67  0.06, P 	 0.001). As
shown in Fig. 4, EPO administration attenuated the NF-B
staining seen in CLP rats (CLP: 1.32 0.08; CLPEPO: 0.81
0.09, P 	 0.001).
Late post-CLP effects on IKK- expression. As can be seen
in Fig. 5, cytoplasmic IKK- protein expression at 48 h
postprocedure was markedly higher in the CLP group rats than
in the control group rats (207.5  7.5 vs. 99.3  0.7%, P 	
0.001). Although such expression was higher in the CLP group
than in the CLPEPO group (207.5  7.5 vs. 142.5  4.8%,
P 	 0.001), it was also higher in the CLPEPO group than in
the control group (142.5  4.8 vs. 99.3  0.7%, P 	 0.001).
Late post-CLP EPO effects on eNOS protein expression. At 48
h after the surgical procedures, the CLP group rats demon-
strated markedly lower eNOS protein expression (% of normal)
compared with the control rats (28.3  6 vs. 93  3.3%, P 	
0.001). It is of note that EPO administration completely pre-
vented the downregulation of eNOS expression (CLPEPO:
90  6.0%; CLP: 28.3  6%, P 	 0.001), as can be seen in
Fig. 6.
Renal effects of coadministration of EPO and L-NAME. Of
the 10 rats in the CLPEPOL-NAME group, only 4 survived
until 24 h after the surgical procedure. At 24 h after CLP, inulin
clearance was significantly lower in CLPEPOL-NAME rats
than in CLPEPO rats (0.64  0.05 vs. 0.99  0.12
ml·min1·100 g BW1, P 	 0.05), although there was no
significant difference between the CLPEPOL-NAME rats
and the CLP rats (0.64  0.05 vs. 0.43  0.08 ml·min1·100
g BW1). As expected, MAP was significantly higher in the
CLPEPOL-NAME group than in the CLP and CLPEPO
groups (155.5  4.1 vs. 74  7.5 and 99  2.3 mmHg, P 	
0.001 for both). The difference between the CLPEPO and
CLP groups, in terms of MAP, was also statistically significant
(P 	 0.01).
Late post-CLP EPO effects on EpoR protein expression.
Expression of EpoR was markedly lower in CLP rats than in
control rats (27.5  4.5 vs. 100  0.6%, P 	 0.001). As can
be seen in Fig. 7, EPO administration completely averted the
downregulation of EpoR observed in the CLP rats (94.2  3.2
vs. 27.5  4.5%, P 	 0.001).
Late post-CLP EPO effects on histological lesions. By 48 h
after CLP, the CLP and CLPEPO rats had developed inter-
stitial lesions. The degree of interstitial damage in the CLP
group was statistically different from that observed for the
control group (2.0  0.29 vs. 0.19  0.09, P 	 0.001). In the
CLPEPO group, the interstitial damage did not progress and
the histological score was significantly lower than that calcu-
lated for the CLP group (1.0  0.16 vs. 2.0  0.29, P 	 0.01).
Fig. 3. ED1 positivity (cells/0.245 mm2) in the tubulointerstitium at 48 h after CLP or sham surgery. A: control group rat. B: CLP group rat. C: CLPEPO group
rat. D: graph (ED1 positivity). Values are means  SE.
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However, the extent of the histological lesions seen in the
CLPEPO group was higher than that seen in the control
group (P 	 0.01).
EPO administration decreases cytokine levels in kidney
tissue. Using a multiplex assay in renal tissue extracts, we
demonstrated that CLP rats presented elevated renal protein
levels of IL-1a, IL-1b, IL-2, IL-4, IL-6, IL-10, IFN-, and
TNF- compared with extracts of renal tissue obtained from
control animals at 48 h after CLP. We also attempted to
determine whether pre-CLP administration of EPO can affect
the renal levels of these cytokines in this model. As shown in
Table 2, EPO administration restored cytokines in kidney
tissue to levels comparable to those observed in control ani-
mals.
EPO effects on survival in polymicrobial sepsis. Mortality
was significantly lower in the CLPEPO group than in the
CLP group (Fig. 8). Among the rats receiving a single dose of
EPO and not subjected to CLP, hematocrit levels at 5 wk after
EPO administration were comparable to those seen in the
control group (42.2 1.5 vs. 39.6 2.2%). None of those rats
developed thrombi or showed any clinical manifestations con-
sistent with stasis, thrombosis, or other complications, all
remaining clinically well throughout the evaluation period.
EPO treatment 4 h post-CLP procedure rescues rat kidney
from AKI. In clinical settings, practitioners rarely have the
chance to anticipate sepsis-induced AKI and are typically
confronted with the syndrome after it has become established.
Therefore, to be worthwhile, any AKI treatment given after the
development of sepsis must be efficacious. To test whether
EPO treatment after CLP might still exert therapeutic effects
on AKI, we administered EPO 1 and 4 h after CLP. Admin-
istration of EPO was effective in restoring renal function.
Inulin clearance at 24 h postprocedure was lower in the CLP
Fig. 4. Immunostaining scores for NF-B in the tubulointerstitial area of the renal cortex at 48 h after CLP or sham surgery. A: control group rat. B: CLP group
rat. C: CLPEPO group rat. D: graph (immunostaining scores). Values are means  SE.
Fig. 5. Semiquantitative immunoblotting of cytoplasmic kidney fractions and
densitometric analysis of samples from control, CLP, and CLPEPO rats.
Immunoblots reacted with anti-IKK- antibody, revealing an 85-kDa band.
Differences among the means were compared by ANOVA followed by the
Student-Newman-Keuls test.
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rats than in the control rats (0.43  0.08 vs. 0.83  0.04
ml·min1·100 g BW1; P 	 0.01). At the same time point,
inulin clearance was also significantly lower in the CLP rats
than in the CLPEPOtreat rats (0.43  0.08 vs. 0.82  0.08
ml·min1·100 g BW1; P 	 0.01). There was no significant
difference between the CLPEPOtreat rats and the control
rats.
DISCUSSION
In rats, the experimental model of CLP, which mimics the
clinical features of bowel perforation and mixed bacterial
infection of intestinal origin in humans, is a realistic model of
polymicrobial sepsis (12). Using the CLP model, we evaluated
the effects of EPO on sepsis-induced AKI. Based on a previous
report by Holly et al. (23), animals were treated with fluid
resuscitation and broad-spectrum antibiotics, which makes this
model even more clinically relevant. To mimic the delay
typically seen in the presentation of human sepsis, fluid resus-
citation and antibiotic treatment were not started until 6 h after
surgery, although some fluid was administered immediately
after the induction of sepsis to replace initial surgical losses.
We found that EPO administration improved survival and
renal function. In the CLPEPO rats, the systemic hemody-
namic and metabolic acid-base status remained unchanged at
24 h after CLP. At 48 h after the surgery, CLPEPO rats
presented stable kidney function, as well as lower renal NF-B
activation, a decrease in fractional interstitial area, less renal
macrophage infiltration, and greater renal eNOS protein ex-
pression, compared with control rats.
The response to EPO administration, in terms of renal
function (as quantified by measuring creatinine clearance), was
homogeneous at 48 h after surgery, translating to a complete
prevention of the decreased glomerular filtration seen in re-
sponse to sepsis. In the CLPEPOtreat rats, renal function was
completely restored by 24 h after surgery. In the picric acid
assay (the most common method of determining creatinine
Fig. 6. Semiquantitative immunoblotting of kidney fractions and densitometric
analysis of samples from control (n 10), CLP (n 10), and CLPEPO (n
10) rats. Immunoblots reacted with anti-endothelial nitric oxide synthase
(eNOS) antibody, revealing a 140-kDa band. Differences among the means
were compared by ANOVA followed by the Student-Newman-Keuls test.
Fig. 7. Semiquantitative immunoblotting of kidney fractions and densitometric
analysis of samples from control, CLP, and CLPEPO rats. Immunoblots
reacted with anti-EPO receptor (EpoR) antibody, revealing a 59-kDa band.
Differences among the means were compared by ANOVA followed by the
Student-Newman-Keuls test.
Table 2. Effects of erythropoietin on levels of
proinflammatory cytokines in the kidney at 48 h after cecal
ligation and puncture
Cytokine Control CLP CLPEPO
IL-1a 4.3 1.0 12.6  4.8 3.0  0.2
IL-1b 45.1 6.7 285.2 136 47.2  5.1
IL-2 10 2.3 56.4  27 9.0  0.4
IL-4 14.6 0.8 85.7 41.1 9.5  0.4
IL-6 50.3 21.3 108.3 38.7 33.4  2.2
IL-10 42 14.4 141.1 64.1 33.1  2.4
CSF 2.1 0.1 15.1  6.6 3.5  1.2
IFN- 24.0  4.4 89.6 38 18.5  1.5
TNF- 41.0  2.3 230.6 109.1 29.7  1.0
Values are means  SE expressed as pg cytokine/g protein. CSF, colony-
stimulating factor.
Fig. 8. Survival of rats subjected to CLP, treated or not treated with erythro-
poietin (EPO). CLP group (n  9); CLPEPO group (n  7).
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clearance), chromagens in serum have been shown to result in
a overestimation of serum creatinine (32, 50). In addition,
reduced production of creatinine limits its use as a marker of
kidney injury in sepsis (14). Therefore, at 24 h after surgery,
we performed inulin clearance studies to determine whether
EPO protects against sepsis-related AKI. As expected, inulin
clearance was reduced in the CLP group. Two previous studies
in mice have shown that EPO has a renoprotective effect on
renal function in sepsis. The first was performed using the LPS
model of sepsis (35). The authors found that EPO, given 30
min before LPS administration, significantly attenuated sepsis-
related renal dysfunction, as assessed by inulin clearance. In
that study, the renal dysfunction observed during endotoxemia
was found to be associated with a decrease in renal superoxide
dismutase, and the EPO-related renal protection was associated
with the reversal of that effect. The second of those two studies
employed LPS and CLP models (3). The authors administered
EPO at different time points after the induction of sepsis. In the
LPS model, serum levels of creatinine were reduced in the
EPO-treated endotoxemic mice.
The cytokine EPO has emerged as having cytoprotective
effects, including the ability to protect many tissues, such as
the brain, heart, and kidneys, against ischemia and traumatic
injury. It has been reported that treatment with EPO protects
the kidney against ischemia-reperfusion injury (27, 37, 40, 45).
It has also been shown that EPO is stimulated during hypoxia
and that it upregulates erythroid progenitor cell proliferation
and differentiation by inhibiting apoptosis (29). The major
physiological function of EPO is the induction of erythropoi-
esis (18).
Anemia is quite common in critically ill patients, especially
in those with AKI. In such patients, erythropoiesis is impaired
as a consequence of blunted EPO production and the direct
inhibitory effects of inflammatory cytokines (15). In a study
involving patients admitted to a long-term acute care facility,
weekly administration of EPO resulted in significantly less
exposure to allogeneic red blood cell transfusion and signifi-
cantly higher hemoglobin levels than did a placebo (43).
We demonstrated protection of hemodynamic parameters in
animals receiving EPO and subjected to CLP. Two recent
studies found that EPO administration attenuates hemorrhagic
and zymosan-induced shock in rats (1, 10).
It is now known that EpoRs are expressed on vascular
endothelial cells (2, 48), which suggests that the vasculature is
a biological target of EPO. It has been demonstrated that EPO
prevents LPS-induced vascular hyporeactivity and endothelial
dysfunction (11), and that the vascular-protective effects of
EPO are critically dependent on the activation of eNOS (16). In
the present study, we observed a profound decrease in eNOS
protein expression in septic animals and that decrease was
prevented in rats receiving EPO before CLP, the latter present-
ing levels of eNOS protein expression comparable to those
seen in the sham-operated animals. In addition, as was the case
for pre-CLP administration of EPO alone, the pre-CLP coad-
ministration of EPO and L-NAME (an inhibitor of NOS activ-
ity) had no apparent protective effect on renal function, as
measured by inulin clearance, indicating that the beneficial
effects of EPO treatment are mediated, in part, by NO produc-
tion. Another interesting finding was that, although MAP was
higher in the CLPEPOL-NAME group than in the CLP and
CLPEPO groups, the addition of L-NAME also had no
apparent protective effect on renal function. We can therefore
conclude that the EPO-related protection of renal function was
not mediated by increased blood pressure.
We found that arterial lactate levels were markedly elevated
in the CLP group, an alteration that was effectively prevented
by EPO administration. In addition, EPO administration pre-
served bicarbonate levels, which typically decrease during
sepsis. Although it is often accompanied by hemodynamic
instability, hyperlactatemia can also occur under stable hemo-
dynamic conditions, in which case it is considered to be due to
occult hypoperfusion (25). In a study employing a murine
model of CLP-induced sepsis, EPO was given in a smaller
dose than that used in the present study (28). The authors
found that EPO had no effect on blood pressure or lactate
levels but produced an increase in capillary perfusion in
skeletal muscle. In a cohort study of 830 adults admitted to
the emergency room with severe sepsis, the initial serum
lactate level was associated with mortality, independent of
organ dysfunction and shock (34).
We found that EPO exerts certain anti-inflammatory effects,
such as preventing the increases in fractional interstitial area
and in the number of infiltrating macrophages/monocytes. We
also demonstrated that treatment with EPO maintained cyto-
kines in renal tissue extracts at sham levels. In this model of
sepsis, EPO also inhibited NF-B expression, which is acti-
vated by a variety of pathogens known to cause septic shock
syndrome (31). Cytoplasmic IKK- protein expression was
upregulated in the CLP group animals, an effect that was
minimized in the in the CLPEPO group animals. It is known
that, in the cytoplasm, the inhibitory protein IB maintains the
transcription factor NF-B in an inactive form. Activation of
NF-B and its migration to the nucleus requires that IB be
phosphorylated on specific serine residues (Ser), which results
in targeted degradation of IB. The interaction between IKK-
and IB- results in specific phosphorylation of IB- at Ser
32 and Ser 36, the sites that trigger its degradation. In addition,
IKK- appears to be critical for NF-B activation in response
to increased production of proinflammatory cytokines (20). In
patients with sepsis, higher levels of NF-B activity are asso-
ciated with higher mortality rates and worse clinical outcomes,
since NF-B mediates the transcription of an exceptionally
large number of genes, the products of which are known to
play important roles in the pathophysiology of sepsis (31).
Inhibition of NF-B activation restores systemic hypotension,
ameliorates septic myocardial dysfunction and vascular de-
rangement, inhibits multiple proinflammatory gene expression,
diminishes intravascular coagulation, reduces tissue neutrophil
influx, and prevents microvascular endothelial leakage (31).
Studies using a CLP model have shown that inhibition of
NF-B activation significantly improves survival (22, 30, 33).
The anti-inflammatory effects of EPO have been well de-
scribed. In a recent study employing a rat model of LPS-
induced endotoxemia, it was demonstrated that EPO attenuates
pulmonary inflammation and suppresses overproduction of
TNF-, which was partially mediated by NF-B inhibition
(39). In addition, treatment with SN-50, a specific inhibitor of
the p50 subunit of NF-B, in combination with antibiotic
therapy, results in a significant survival benefit in the CLP
model (36). Furthermore, NF-B is responsible for a broad
spectrum of responses, including inflammatory/immunoregu-
latory functions, apoptosis, adhesion molecule production, and
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cell cycle regulation (31). Our data indicate that EPO protects
renal function and that this renoprotective affect is, in part,
attributable to inhibition of the inflammatory response via
downregulation of NF-B activation. We hypothesized that
EPO decreases NF-B protein expression and consequently
decreases inflammatory cytokine expression via EpoRs.
Endre et al. (17) conducted a controlled trial, designated the
EARLYARF study, to determine whether a high dose of EPO
(up to 50,000 U) would prevent AKI in intensive care unit
patients if administered early (within 6 h of injury). To select
patients for treatment, the authors measured urinary levels of
the proximal tubular brush-border enzymes -glutamyl trans-
peptidase and alkaline phosphatase, both of which are bio-
markers of kidney injury. Patients in whom the levels of those
biomarkers exceeded the thresholds were randomized to re-
ceive either placebo or two doses of EPO. Although early
intervention with high-dose EPO was found to be safe, it did
not alter outcomes. Although elevated levels of -glutamyl
transpeptidase and alkaline phosphatase were efficient in pre-
dicting poorer outcomes, they were hardly predictive of AKI,
with a receiver operating characteristic curve of 0.54. In
addition, the primary outcome measure was an increase in the
mean creatinine level relative to baseline over 4–7 days.
Consequently, AKI was identified through post hoc analysis. It
is obvious that such diverse criteria can affect diagnostic
accuracy.
Our results clearly indicate that the beneficial effects of EPO
treatment are mediated, in part, by the higher production of
NO, as evidenced by the higher levels of eNOS protein ex-
pression. We have demonstrated that, in a rat model of poly-
microbial sepsis that mimics human sepsis, EPO provides a
benefit due to its anti-inflammatory properties and its ability to
upregulate eNOS protein expression.
In conclusion, treatment with EPO exhibited anti-inflamma-
tory effects, improved systemic hemodynamics, and provided a
significant survival benefit in rats subjected to CLP. We have
also demonstrated that, in this CLP model of sepsis, EpoR
expression is downregulated.
In the setting of sepsis, EPO administration, in addition to
downregulating NF-B activation, might have an endothelial
protective effect, attributable to an EPO-induced increase in
eNOS protein expression.
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